Com­pa­nies pre­sent­ing


Am­ryt Pharma Rory Nealon, CFO & COO

Am­ryt Pharma is a spe­cialty bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing and de­liv­er­ing in­no­va­tive new treat­ments to help im­prove the lives of pa­tients with rare or or­phan dis­eases. The Com­pany is build­ing a di­ver­si­fied port­fo­lio of com­mer­cially at­trac­tive, best-in-class, pro­pri­etary new drugs to help ad­dress some of these rare and de­bil­i­tat­ing ill­nesses for which there are cur­rently no avail­able treat­ments.

Di­ur­nal Martin Whi­taker, CEO

Founded in 2004, Di­ur­nal is a UK-based, glob­ally-fo­cused spe­cialty pharma com­pany de­vel­op­ing high qual­ity prod­ucts for the life-long treat­ment of chronic en­docrine con­di­tions. It is com­mit­ted to ad­dress­ing ma­jor un­met clin­i­cal and pa­tient needs in hor­mone re­place­ment, ini­tially by de­vel­op­ing and mar­ket­ing prod­ucts for the rare or­phan dis­eases Con­gen­i­tal Adrenal Hyper­pla­sia (CAH) and Adrenal In­suf­fi­ciency (AI).

Mi­dat­ech Pharma Speaker TBC

Mi­dat­ech is a nanomedicine com­pany fo­cused on the de­vel­op­ment and com­mer­cial­i­sa­tion of mul­ti­ple, high-value, tar­geted ther­a­pies for ma­jor dis­eases with un­met med­i­cal need. It is ad­vanc­ing a pipe­line of novel clin­i­cal and pre-clin­i­cal prod­uct can­di­dates based on its pro­pri­etary drug con­ju­gate and sus­tained re­lease de­liv­ery plat­forms with a clear fo­cus on the key ther­a­peu­tic ar­eas of di­a­betes, cancer and neu­ro­science/oph­thal­mol­ogy.

NetS­ci­en­tific Fran­cois Martelet, CEO

NetS­ci­en­tific is a bio­med­i­cal and tran­sat­lantic health­care tech­nol­ogy group with an in­vest­ment strat­egy fo­cused on sourc­ing, fund­ing and com­mer­cial­is­ing tech­nolo­gies that sig­nif­i­cantly im­prove the health and well-be­ing of peo­ple with chronic dis­eases. NetS­ci­en­tific funds, develops and man­ages early/mid-stage health­care tech­nol­ogy com­pa­nies sourced from strate­gic part­ner­ships and re­la­tion­ships in USA and Europe with a pri­mary fo­cus on Dig­i­tal health, Di­ag­nos­tics and Ther­a­peu­tics.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.